Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2017

04.07.2017 | Original Article

A new integrated dual time-point amyloid PET/MRI data analysis method

verfasst von: Diego Cecchin, Henryk Barthel, Davide Poggiali, Annachiara Cagnin, Solveig Tiepolt, Pietro Zucchetta, Paolo Turco, Paolo Gallo, Anna Chiara Frigo, Osama Sabri, Franco Bui

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In the initial evaluation of patients with suspected dementia and Alzheimer’s disease, there is no consensus on how to perform semiquantification of amyloid in such a way that it: (1) facilitates visual qualitative interpretation, (2) takes the kinetic behaviour of the tracer into consideration particularly with regard to at least partially correcting for blood flow dependence, (3) analyses the amyloid load based on accurate parcellation of cortical and subcortical areas, (4) includes partial volume effect correction (PVEC), (5) includes MRI-derived topographical indexes, (6) enables application to PET/MRI images and PET/CT images with separately acquired MR images, and (7) allows automation.

Methods

A method with all of these characteristics was retrospectively tested in 86 subjects who underwent amyloid (18F-florbetaben) PET/MRI in a clinical setting (using images acquired 90–110 min after injection, 53 were classified visually as amyloid-negative and 33 as amyloid-positive). Early images after tracer administration were acquired between 0 and 10 min after injection, and later images were acquired between 90 and 110 min after injection. PVEC of the PET data was carried out using the geometric transfer matrix method. Parametric images and some regional output parameters, including two innovative “dual time-point” indexes, were obtained.

Results

Subjects classified visually as amyloid-positive showed a sparse tracer uptake in the primary sensory, motor and visual areas in accordance with the isocortical stage of the topographic distribution of the amyloid plaque (Braak stages V/VI). In patients classified visually as amyloid-negative, the method revealed detectable levels of tracer uptake in the basal portions of the frontal and temporal lobes, areas that are known to be sites of early deposition of amyloid plaques that probably represented early accumulation (Braak stage A) that is typical of normal ageing. There was a strong correlation between age and the indexes of the new dual time-point amyloid imaging method in amyloid-negative patients.

Conclusions

The method can be considered a valuable tool in both routine clinical practice and in the research setting as it will standardize data regarding amyloid deposition. It could potentially also be used to identify early amyloid plaque deposition in younger subjects in whom treatment could theoretically be more effective.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997–1005.CrossRefPubMedPubMedCentral
2.
Guerra UP, Nobili FM, Padovani A, Perani D, Pupi A, Sorbi S, et al. Recommendations from the Italian interdisciplinary working group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci. 2015;36(6):1075–81.CrossRefPubMed
3.
4.
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74.CrossRefPubMed
5.
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78.CrossRefPubMed
6.
Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398–403.CrossRefPubMedPubMedCentral
7.
8.
9.
10.
Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251–9.CrossRefPubMed
11.
Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36:S159–66.CrossRefPubMed
12.
Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39(4):621–31.CrossRefPubMedPubMedCentral
13.
Hutton C, Declerck J, Mintun MA, Pontecorvo MJ, Devous MD Sr, Joshi AD; Alzheimer’s Disease Neuroimaging Initiative. Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging. 2015;42(5):725–32.CrossRefPubMed
14.
Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55(10):1623–8.CrossRefPubMed
15.
Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, et al. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis. 2016;54(4):1437–57.CrossRefPubMed
16.
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702–14.CrossRefPubMed
17.
Saint-Aubert L, Nemmi F, Péran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41(5):836–43.CrossRefPubMed
18.
van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570–6.CrossRefPubMed
19.
Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med. 2013;54(5):723–31.CrossRefPubMed
20.
Matsubara K, Ibaraki M, Shimada H, Ikoma Y, Suhara T, Kinoshita T, et al. Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with 11C PiB PET. Neuroimage. 2016;143:316–24.
21.
Rodell AB, O’Keefe G, Rowe CC, Villemagne VL, Gjedde A. Cerebral blood flow and Aβ-amyloid estimates by WARM analysis of 11C PiB uptake distinguish among and between neurodegenerative disorders and aging. Front Aging Neurosci. 2017;8:321.CrossRefPubMedPubMedCentral
22.
Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT, et al. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1700–9.CrossRefPubMed
23.
Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.CrossRefPubMed
24.
Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 2004;22:1060–75.CrossRefPubMed
25.
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRefPubMed
26.
Fischl B, Salat DH, van der Kouwe AJ, Makris N, Ségonne F, Quinn BT, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23(Suppl 1):S69–84.CrossRefPubMed
27.
Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87–97.CrossRefPubMed
28.
Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20:70–80.CrossRefPubMed
29.
Segonne F, Pacheco J, Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med Imaging. 2007;26:518–29.CrossRefPubMed
30.
Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.CrossRefPubMed
31.
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050–5.CrossRefPubMedPubMedCentral
32.
Mazziotta JC, Toga AW, Evans AC, Fox P, Lancaster J, Zilles K, et al. A four-dimensional probabilistic atlas of the human brain. J Am Med Inform Assoc. 2001;8(5):401–30.CrossRefPubMedPubMedCentral
33.
Rullmann M, Dukart J, Hoffmann KT, Luthardt J, Tiepolt S, Patt M, et al. Partial volume effect correction improves quantitative florbetaben beta-amyloid PET scan analysis. J Nucl Med. 2016;57(2):198–203.CrossRefPubMed
34.
Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19.CrossRefPubMed
35.
Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904–11.PubMed
36.
Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 2008;49(7):1097–106.CrossRefPubMedPubMedCentral
37.
Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450–9.CrossRefPubMed
38.
Teipel S, Drzezga A, Grothe MJ, Barthel H, Chételat G, Schuff N, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14(10):1037–53.CrossRefPubMed
39.
Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD Sr, et al. Semiautomated method for quantification of F18 florbetapir PET images. J Nucl Med. 2015;56(11):1736–41.CrossRefPubMed
40.
Schain M, Varnäs K, Cselényi Z, Halldin C, Farde L, Varrone A. Evaluation of two automated methods for PET region of interest analysis. Neuroinformatics. 2014;12(4):551–62.CrossRefPubMed
41.
Lilja J, Thurfjell L, Sörensen J. Visualization and quantification of 3-dimensional stereotactic surface projections for 18F-Flutemetamol PET using variable depth. J Nucl Med. 2016;57(7):1078–83.CrossRefPubMed
42.
Lundqvist R, Lilja J, Thomas BA, Lötjönen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472–8.CrossRefPubMed
43.
Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS One. 2014;9(1):e84777.CrossRefPubMedPubMedCentral
44.
Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2013;70:423–33.CrossRefPubMed
45.
Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61(15):5768–80.CrossRefPubMed
46.
Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8(11):e73377.CrossRefPubMedPubMedCentral
47.
Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1077–87.CrossRefPubMed
48.
Su Y, Blazey TM, Snyder AZ, Raichle ME, Hornbeck RC, Aldea P, et al. Quantitative amyloid imaging using image-derived arterial input function. PLoS One. 2015;10(4):e0122920.CrossRefPubMedPubMedCentral
49.
Ikoma Y, Edison P, Ramlackhansingh A, Brooks DJ, Turkheimer FE. Reference region automatic extraction in dynamic [(11)C]PIB. J Cereb Blood Flow Metab. 2013;33(11):1725–31.CrossRefPubMedPubMedCentral
50.
Heurling K, Buckley C, Van Laere K, Vandenberghe R, Lubberink M. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol. Neuroimage. 2015;121:184–92.CrossRefPubMed
51.
Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer’s disease: results from the DIAN study group. PLoS One. 2016;11(3):e0152082.CrossRefPubMedPubMedCentral
52.
Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991;1:103–16.CrossRefPubMed
53.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed
54.
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.CrossRefPubMedPubMedCentral
55.
Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease. Brain. 2016;139(Pt 9):2528–39.CrossRefPubMed
56.
Metadaten
Titel
A new integrated dual time-point amyloid PET/MRI data analysis method
verfasst von
Diego Cecchin
Henryk Barthel
Davide Poggiali
Annachiara Cagnin
Solveig Tiepolt
Pietro Zucchetta
Paolo Turco
Paolo Gallo
Anna Chiara Frigo
Osama Sabri
Franco Bui
Publikationsdatum
04.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3750-0

Weitere Artikel der Ausgabe 12/2017

European Journal of Nuclear Medicine and Molecular Imaging 12/2017 Zur Ausgabe

Original Article

Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F–DOPA PET

Letter to the Editor

About the specificity of radiotracers for prostate cancer

Review Article

Bone SPECT/CT in the postoperative spine: a focus on spinal fusion

Original Article

The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma

Original Article

Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection

Image of the Month

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET